FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
Portfolio Pulse from Juan Spínelli
Incannex Healthcare Inc. (NASDAQ:IXHL) has received FDA approval to proceed with a phase 2 clinical trial for its psilocybin-assisted therapy for generalized anxiety disorder. The trial, PsiGAD2, aims to replicate and expand on positive results from a previous study, with plans to enroll 94 patients. The company is also seeking approval in the UK.
August 05, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex Healthcare Inc. (NASDAQ:IXHL) has received FDA approval to proceed with a phase 2 clinical trial for its psilocybin-assisted therapy for generalized anxiety disorder. This approval follows positive results from an earlier study and could significantly impact the company's stock price.
The FDA approval for a phase 2 trial is a significant milestone for Incannex, indicating regulatory confidence in their psilocybin-assisted therapy. Positive results from the previous study and the potential for further validation in the upcoming trial could drive investor optimism and positively impact the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100